EP2658541B2 - Topisch lokalisierte isoxazolinformulierung mit glycofurol - Google Patents

Topisch lokalisierte isoxazolinformulierung mit glycofurol

Info

Publication number
EP2658541B2
EP2658541B2 EP11799292.5A EP11799292A EP2658541B2 EP 2658541 B2 EP2658541 B2 EP 2658541B2 EP 11799292 A EP11799292 A EP 11799292A EP 2658541 B2 EP2658541 B2 EP 2658541B2
Authority
EP
European Patent Office
Prior art keywords
formulation
topical localized
compound
solvent
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11799292.5A
Other languages
English (en)
French (fr)
Other versions
EP2658541B1 (de
EP2658541A1 (de
Inventor
Stefan Fuchs
Anja Regina Heckeroth
Ramona MÜLLER
Heike Williams
Hartmut Zoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43920659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2658541(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to PL11799292T priority Critical patent/PL2658541T3/pl
Publication of EP2658541A1 publication Critical patent/EP2658541A1/de
Publication of EP2658541B1 publication Critical patent/EP2658541B1/de
Application granted granted Critical
Publication of EP2658541B2 publication Critical patent/EP2658541B2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

  1. Eine topische lokal begrenzte Spot-on- oder Pour-on-Formulierung zur Verwendung bei der Behandlung oder Prophylaxe von Floh- und Zeckenbefall bei Hunden oder Katzen, die eine wirksame Menge von mindestens einer Isoxazolin-Verbindung umfasst, nämlich 4-[5-(3,5-Dichlorphenyl)-5-trifluormethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluorethylcarbamoyl)-methyl]-benzamid, und ein veterinärmedizinisch akzeptables flüssiges Trägervehikel, wobei das flüssige Trägersystem Glycofurol als Lösungsmittel und ein Co-Lösungsmittel ausgewählt aus der Gruppe bestehend aus Aceton, Acetonitril, Benzylalkohol, Butyl-Diglykol, Dimethylacetamid, Dimethylsulfoxid, Dimethylformamid, N,N-Diethyl-3-methylbenzamid, Dipropylenglykol-n-Butylether, Ethanol, Isopropanol, Methanol, Phenylethylalkohol, Isopropanol, EthylenglykolMonoethylether, Ethylenglykol-Monomethylether, Monomethylacetamid, Dipropylenglykol-Monomethylether, flüssigen Polyoxyethylen-Glykolen, Propylenglykol, N-Methylpyrrolidon, 2-Pyrrolidon, Limonen, Eucalyptol, Diethylenglykol-Monoethylether, Ethylenglykol, Diethylphthalat, polyethoxylierte Rizinusöl, Methylethylketon, Ethyl-L-Lactat und einer Mischung aus mindestens zwei dieser Co-Lösungsmittel umfasst;
    die Formulierung umfasst 20 - 35 % w/v der Isoxazolin-Verbindung in einem Anwendungsvolumen von 0,3 bis 6 ml pro Tier; mit langanhaltender Wirksamkeit gegen Zecken und Flöhe, sodass die Verabreichung monatlich, alle 2 Monate, 3 Monate, 4 Monate, 5 Monate oder 6 Monate erfolgt.
  2. Die topische lokal begrenzte Formulierung zur Verwendung gemäß Anspruch 1, wobei das flüssige Trägervehikel Glycofurol als Lösungsmittel und ein Co-Lösungsmittel ausgewählt aus der Gruppe bestehend aus Dimethylsulfoxid, Aceton, Dimethylacetamid, N,N-Diethyl-3-methylbenzamid, Ethanol, Eucalyptol, Dipropylenglykol-Monomethylether, Methylethylketon, Ethyl-L-Lactat und einer Mischung aus mindestens zwei dieser Co-Lösungsmittel umfasst.
  3. Die topische lokal begrenzte Formulierung zur Verwendung gemäß Anspruch 2, wobei das flüssige Trägersystem Glycofurol als Lösungsmittel umfasst und das organische Co-Lösungsmittel in der Spot-on-Zusammensetzung eine Mischung aus mindestens zwei von Aceton, Ethyl-L-Lactat, Dimethylsulfoxid, Dimethylacetamid und N,N-Diethyl-3-methylbenzamid ist.
  4. Die topische lokal begrenzte Formulierung zur Verwendung gemäß den Ansprüchen 1 bis 3, wobei die Zusammensetzung zusätzlich eine wirksame Menge einer makrozyklischen Laktone-Verbindung umfasst, die aus Moxidectin, Milbemycin-Oxim, Selamectin, Emamectin, Latidectin und Lepimectin oder einem Salz davon ausgewählt ist und/oder eine Insektenwachstumsregulatorverbindung, die aus Fenoxycarb, Lufenuron, Diflubenzuron, Novaluron, Triflumuron, Fluazuron, Cyromazin, Methopren und Pyriproxyfen ausgewählt ist.
  5. Die topische lokal begrenzte Formulierung zur Verwendung gemäß Anspruch 4, wobei die Zusammensetzung eine wirksame Menge von 4-[5-(3,5-Dichlorphenyl)-5-trifluormethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluorethylcarbamoyl)-methyl]-benzamid und eine wirksame Menge von Moxidectin umfasst.
  6. Die topische lokal begrenzte Formulierung zur Verwendung gemäß den Ansprüchen 1 bis 5, wobei ein Anwendungsvolumen von 0,4 bis 2,0 ml der topischen lokal begrenzten Formulierung an Katzen verabreicht wird.
  7. Die topische lokal begrenzte Formulierung zur Verwendung gemäß den Ansprüchen 1 bis 5, wobei ein Anwendungsvolumen von 0,4 bis 5,0 ml der topischen lokal begrenzten Formulierung an Hunde verabreicht wird.
EP11799292.5A 2010-12-27 2011-12-22 Topisch lokalisierte isoxazolinformulierung mit glycofurol Active EP2658541B2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL11799292T PL2658541T3 (pl) 2010-12-27 2011-12-22 Preparat izoksazoliny do stosowania miejscowego zawierający glikofurol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10197090 2010-12-27
US201161430241P 2011-01-06 2011-01-06
PCT/EP2011/073830 WO2012089623A1 (en) 2010-12-27 2011-12-22 Topical localized isoxazoline formulation comprising glycofurol

Publications (3)

Publication Number Publication Date
EP2658541A1 EP2658541A1 (de) 2013-11-06
EP2658541B1 EP2658541B1 (de) 2022-01-26
EP2658541B2 true EP2658541B2 (de) 2025-12-17

Family

ID=43920659

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11799292.5A Active EP2658541B2 (de) 2010-12-27 2011-12-22 Topisch lokalisierte isoxazolinformulierung mit glycofurol

Country Status (18)

Country Link
US (2) US20130274302A1 (de)
EP (1) EP2658541B2 (de)
JP (3) JP2014506249A (de)
KR (2) KR101992589B1 (de)
CN (2) CN108125951A (de)
AU (1) AU2011351579B2 (de)
BR (1) BR112013015498A2 (de)
CA (1) CA2822853C (de)
DK (1) DK2658541T3 (de)
ES (1) ES2908254T3 (de)
HU (1) HUE058290T2 (de)
MX (2) MX348079B (de)
NZ (1) NZ611474A (de)
PL (1) PL2658541T3 (de)
PT (1) PT2658541T (de)
RU (1) RU2602189C2 (de)
WO (1) WO2012089623A1 (de)
ZA (1) ZA201304515B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992589B1 (ko) * 2010-12-27 2019-06-24 인터벳 인터내셔널 비.브이. 글리코푸롤을 포함하는 국소 적용 이속사졸린 제제
HUE058291T2 (hu) * 2010-12-27 2022-07-28 Intervet Int Bv Topikális lokalizált izoxazolin formuláció
PT2755473T (pt) 2011-09-12 2019-03-25 Boehringer Ingelheim Animal Health Usa Inc Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
PL232463B1 (pl) 2012-02-06 2019-06-28 Merial Inc Miękka, nadająca się do żucia kompozycja weterynaryjna do leczenia i/lub zapobiegania infekcji lub inwazji pasożytniczej u zwierzęcia oraz jej zastosowanie
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
AU2013201479C1 (en) * 2012-03-13 2017-11-09 Elanco New Zealand Long Acting Compositions
EP3063144B1 (de) 2013-11-01 2021-09-08 Boehringer Ingelheim Animal Health USA Inc. Antiparasitäre und pestizide isoxazolinverbindungen
EP2875726A1 (de) * 2013-11-13 2015-05-27 Ceva Animal Health Neue Anwendungen von veterinärmedizinischen Zusammensetzungen für die Behandlung gegen Parasiten
JP6581586B2 (ja) * 2013-12-20 2019-09-25 インターベット インターナショナル ベー． フェー． イソオキサゾリン組成物および動物における寄生虫侵襲の予防または処置におけるその使用
BR112016014216B1 (pt) * 2013-12-20 2022-08-30 Intervet International B.V. Usos de um composto isoxazolina
CA2945766C (en) 2014-04-17 2023-09-26 Merial, Inc. Use of malononitrile compounds for protecting animals from parasites
AU2015371175B2 (en) 2014-12-22 2021-03-04 Intervet International B.V. Use of isoxazoline compounds for treating demodicosis
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
EP3280413A1 (de) 2015-04-08 2018-02-14 Merial, Inc. Langwirkende injizierbare formulierungen mit einem isoxazolinwirkstoff, verfahren und verwendungen davon
US10081656B2 (en) 2015-05-20 2018-09-25 Merial, Inc. Anthelmintic depsipeptide compounds
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
CN110381738B (zh) 2016-10-14 2021-07-16 勃林格殷格翰动物保健美国公司 农药的和杀寄生物的乙烯基异噁唑啉化合物
WO2018093920A1 (en) 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
WO2019036407A1 (en) 2017-08-14 2019-02-21 Merial, Inc. PYRAZOLE-ISOXAZOLINE COMPOUNDS WITH PESTICIDE AND PARASITICIDE ACTIVITY
AU2018372008B2 (en) * 2017-11-23 2024-03-28 Ceva Sante Animale Composition containing moxidectin for treating parasites infestations
AR113997A1 (es) 2017-12-21 2020-07-08 Intervet Int Bv Composiciones antiparasitarias para unción dorsal continua
PE20211275A1 (es) 2018-07-09 2021-07-19 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos
EP3883648A1 (de) 2018-11-20 2021-09-29 Boehringer Ingelheim Animal Health USA Inc. Indazolylcyanoethylaminoverbindung, zusammensetzungen davon, verfahren zur herstellung und verfahren zur verwendung davon
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
PH12021552713A1 (en) * 2019-05-03 2022-07-04 Intervet Int Bv Injectable pharmaceutical compositions and uses thereof
CA3147431A1 (en) 2019-07-16 2021-01-21 Donaghys Limited Transdermal solvent system and methods of use
AU2020408351A1 (en) 2019-12-18 2022-08-11 Elanco Tiergesundheit Ag Isoxazoline derivatives as pesticides
AU2021278871A1 (en) 2020-05-28 2023-01-19 Boehringer Ingelheim Animal Health USA Inc. Bi-modal release intra-ruminal capsule device and methods of use thereof
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
US20230257370A1 (en) 2020-07-24 2023-08-17 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
JP2024504208A (ja) 2020-12-21 2024-01-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー イソオキサゾリン化合物を含む殺寄生虫首輪
US20240116854A1 (en) 2021-01-27 2024-04-11 Intervet Inc. Cyclopropylamide compounds against parasites in fish
JP2024511258A (ja) 2021-01-27 2024-03-13 コルテバ アグリサイエンス エルエルシー 魚における寄生生物に対するシクロプロピルアミド化合物
WO2023156938A1 (en) 2022-02-17 2023-08-24 Boehringer Ingelheim Vetmedica Gmbh Method and system for providing a fluid product mailer
NO20240925A1 (en) 2023-09-15 2025-03-17 Evah Atlantic Inc Dihydroisoxazole compound for use in reducing ectoparasite infestations on fish
WO2025191150A2 (en) * 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Stable isoxazoline formulation for topical application to the skin
WO2025257633A1 (en) 2024-06-12 2025-12-18 Boehringer Ingelheim Vetmedica Gmbh Long-acting castor oil-containing injectable formulations and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018659A1 (en) † 2005-05-16 2007-02-15 Merial Limited Spot-on formulations for combating parasites
WO2009024541A2 (en) † 2007-08-17 2009-02-26 Intervet International B.V. Isoxazoline compositions and their use as antiparasitics
US20100311685A1 (en) † 2007-12-21 2010-12-09 Guy Derrieu Pharmaceutical Composition Containing An N-Phenylpyrazole Derivative And Glycofurol, Use For The Preparation Of A Topical Veterinary Medicament For Combating Fleas
WO2018039508A1 (en) † 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
EP2658542B1 (de) † 2010-12-27 2022-01-26 Intervet International B.V. Topisch lokalisierte isoxazolinformulierung

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984564A (en) 1972-06-08 1976-10-05 Sankyo Company Limited Antibiotic substances B-41, their production and their use as insecticides and acaricides
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
GB8331037D0 (en) * 1983-11-21 1983-12-29 May & Baker Ltd Compositions of matter
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
IL98599A (en) 1990-06-28 1995-06-29 Merck & Co Inc Stable salts of 4"-deoxy-4"-epi-methylamino avermectin b1a/b1b and insecticidal compositions containing them
US5399717A (en) 1993-09-29 1995-03-21 Merck & Co., Inc. Glycosidation route to 4"-epi-methylamino-4"-deoxyavermectin B1
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
BRPI0409185B1 (pt) * 2003-04-04 2018-05-15 Merial, Inc Formulações veterinárias anti-helmínticas tópicas
AU2004280158B2 (en) * 2003-07-18 2011-02-17 Baxter International, Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
DE102004021281A1 (de) 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
PE20060785A1 (es) * 2004-10-08 2006-09-19 Wyeth Corp Composiciones de amitraz
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
EP2957284B1 (de) 2007-06-27 2018-01-17 E. I. du Pont de Nemours and Company Verfahren zur bekämpfung von tierischen schädlingen
ES2442342T3 (es) 2008-12-18 2014-02-11 Novartis Ag Derivados de las isoxazolinas y su uso como pesticida
DK2379537T5 (en) 2008-12-19 2017-09-25 Elanco Tiergesundheit Ag Isoxazoline derivatives and their use as pesticides
WO2010128095A1 (en) 2009-05-07 2010-11-11 Novartis Ag Ectoparasiticidal compositions
NZ600922A (en) 2009-12-17 2013-10-25 Merial Ltd Anti parasitic dihydroazole compounds and compositions comprising same
DK178277B1 (da) * 2010-06-18 2015-10-26 Novartis Tiergesundheit Ag Diaryloxazolinforbindelser til bekæmpelse af fiskelus
KR101992589B1 (ko) * 2010-12-27 2019-06-24 인터벳 인터내셔널 비.브이. 글리코푸롤을 포함하는 국소 적용 이속사졸린 제제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018659A1 (en) † 2005-05-16 2007-02-15 Merial Limited Spot-on formulations for combating parasites
WO2009024541A2 (en) † 2007-08-17 2009-02-26 Intervet International B.V. Isoxazoline compositions and their use as antiparasitics
US20100311685A1 (en) † 2007-12-21 2010-12-09 Guy Derrieu Pharmaceutical Composition Containing An N-Phenylpyrazole Derivative And Glycofurol, Use For The Preparation Of A Topical Veterinary Medicament For Combating Fleas
EP2658542B1 (de) † 2010-12-27 2022-01-26 Intervet International B.V. Topisch lokalisierte isoxazolinformulierung
WO2018039508A1 (en) † 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Ectoparasites - Drug discovery against moving targets", 1 January 2018, WILEY VCH, ISBN: 978-3-527-34168-9, article XU MING, ET AL: "13 The Discovery of Afoxolaner: A New Ectoparasiticide for Dogs", pages: 259 - 271, XP055977348 †
BRAVECTO® SPOT-ON (MARKETING AUTHORIZATION †
OZOE, Y. ET AL: "The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 391, no. 1, 1 January 2010 (2010-01-01), Amsterdam NL , pages 744 - 749, XP026823770, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2009.11.131 †
TAENZLER JANINA, ET AL: "Efficacy of fluralaner spot-on solution against induced infestations with Rhipicephalus sanguineus on dogs", PARASITES & VECTORS, vol. 9, no. 276, 1 January 2016 (2016-01-01), pages 1 - 5, XP055977232 †

Also Published As

Publication number Publication date
MX2013007501A (es) 2013-08-01
BR112013015498A2 (pt) 2016-11-01
AU2011351579A1 (en) 2013-06-20
JP2018154657A (ja) 2018-10-04
PT2658541T (pt) 2022-03-11
CN103260620A (zh) 2013-08-21
US20150011596A1 (en) 2015-01-08
CA2822853A1 (en) 2012-07-05
EP2658541B1 (de) 2022-01-26
ZA201304515B (en) 2014-03-26
DK2658541T3 (da) 2022-04-04
JP2016216489A (ja) 2016-12-22
HUE058290T2 (hu) 2022-07-28
ES2908254T3 (es) 2022-04-28
KR101992589B1 (ko) 2019-06-24
WO2012089623A1 (en) 2012-07-05
MX2019011837A (es) 2019-11-21
KR101920476B1 (ko) 2018-11-21
PL2658541T3 (pl) 2022-04-04
AU2011351579B2 (en) 2016-04-21
MX390508B (es) 2025-03-20
JP2014506249A (ja) 2014-03-13
MX348079B (es) 2017-05-25
JP6357508B2 (ja) 2018-07-11
NZ611474A (en) 2015-08-28
KR20130130762A (ko) 2013-12-02
US20130274302A1 (en) 2013-10-17
CA2822853C (en) 2021-05-11
EP2658541A1 (de) 2013-11-06
RU2602189C2 (ru) 2016-11-10
JP6539384B2 (ja) 2019-07-03
KR20180125618A (ko) 2018-11-23
CN108125951A (zh) 2018-06-08
RU2013135415A (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
EP2658541B2 (de) Topisch lokalisierte isoxazolinformulierung mit glycofurol
AU2017254818B2 (en) Topical localized isoxazoline formulation
AU2011351578B2 (en) Topical localized isoxazoline formulation
KR102193090B1 (ko) 국소 적용 이속사졸린 제제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011072454

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031420000

Ipc: A61K0009080000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20211011BHEP

INTG Intention to grant announced

Effective date: 20211029

RIC1 Information provided on ipc code assigned before grant

Ipc: A01P 7/04 20060101ALI20211015BHEP

Ipc: A01N 43/80 20060101ALI20211015BHEP

Ipc: A61K 47/34 20170101ALI20211015BHEP

Ipc: A61K 47/18 20170101ALI20211015BHEP

Ipc: A61P 33/14 20060101ALI20211015BHEP

Ipc: A61K 31/42 20060101ALI20211015BHEP

Ipc: A61K 9/08 20060101AFI20211015BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1464726

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011072454

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2658541

Country of ref document: PT

Date of ref document: 20220311

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20220308

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220401

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2908254

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220428

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220400651

Country of ref document: GR

Effective date: 20220418

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20220126

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E058290

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220526

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602011072454

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: VIRBAC

Effective date: 20221025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1464726

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220126

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20241111

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20241125

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20241128

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20241114

Year of fee payment: 14

Ref country code: FI

Payment date: 20241126

Year of fee payment: 14

Ref country code: GR

Payment date: 20241125

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241114

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20241111

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20241204

Year of fee payment: 14

Ref country code: AT

Payment date: 20241125

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20241113

Year of fee payment: 14

Ref country code: IE

Payment date: 20241125

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20241202

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20241212

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20241209

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20241121

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250116

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250101

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250915

Year of fee payment: 15

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

REG Reference to a national code

Ref country code: CH

Ref legal event code: M12

Free format text: ST27 STATUS EVENT CODE: U-0-0-M10-M12 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20251125

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251113

Year of fee payment: 15

27A Patent maintained in amended form

Effective date: 20251217

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602011072454

Country of ref document: DE